Results 1 to 10 of about 1,691,494 (417)
South African Family Practice, 2015
Heart failure is a global problem. It is estimated that approximately 38 million people worldwide experience heart failure, and this number is growing because of the ageing of nations’ populations, but also because patients are rescued from death during ...
J. A. Ker
doaj +8 more sources
Heart failure is a global problem. It is estimated that approximately 38 million people worldwide experience heart failure, and this number is growing because of the ageing of nations’ populations, but also because patients are rescued from death during ...
J. A. Ker
doaj +8 more sources
European Journal of Heart Failure, 2019
To provide reliable survival estimates for people with chronic heart failure and explain variation in survival by key factors including age at diagnosis, left ventricular ejection fraction, decade of diagnosis, and study setting.
Andrea K Roalfe+2 more
exaly +2 more sources
To provide reliable survival estimates for people with chronic heart failure and explain variation in survival by key factors including age at diagnosis, left ventricular ejection fraction, decade of diagnosis, and study setting.
Andrea K Roalfe+2 more
exaly +2 more sources
Management of hyperkalaemia in acute kidney injury in a heart failure patient with patiromer [PDF]
ESC Heart Failure, 2020Aims One prevalent comorbidity of chronic heart failure (CHF) is chronic kidney disease(CKD). Hyperkalemia is associated with both CHF and CKD, which often leads to withdrawal of heart failure medications in clinical praxis. Methods and results A patient
Jonathan Slawik+3 more
doaj +2 more sources
Natriuretic Peptides in Chronic Heart Failure
Cardiac Failure Review, 2019Normal brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) levels are helpful in excluding chronic heart failure in the ambulatory setting, although they have been studied less well and possibly less accurately than in acute care.
Hans-Peter Brunner-La Rocca+1 more
doaj +2 more sources
Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure [PDF]
New England Journal of Medicine, 1991BACKGROUND Milrinone, a phosphodiesterase inhibitor, enhances cardiac contractility by increasing intracellular levels of cyclic AMP, but the long-term effect of this type of positive inotropic agent on the survival of patients with chronic heart failure
Milton Packer+14 more
openalex +2 more sources
European Journal of Heart Failure, 2019
Drugs that inhibit the sodium–glucose co‐transporter 2 (SGLT2) have been shown to reduce the risk of hospitalizations for heart failure in patients with type 2 diabetes.
Milton Packer+2 more
exaly +2 more sources
Drugs that inhibit the sodium–glucose co‐transporter 2 (SGLT2) have been shown to reduce the risk of hospitalizations for heart failure in patients with type 2 diabetes.
Milton Packer+2 more
exaly +2 more sources
Transcriptional landscape in rat intestines under hypobaric hypoxia [PDF]
PeerJ, 2021Oxygen metabolism is closely related to the intestinal homeostasis environment, and the occurrence of many intestinal diseases is as a result of the destruction of oxygen gradients.
Liuyang Tian+5 more
doaj +2 more sources
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
European Heart Journal, 2021An engaging session on the newly revised European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of acute and chronic heart failure (HF) was conducted on the first day of the 2021 ESC virtual congress.
T. McDonagh+30 more
semanticscholar +2 more sources
Australian Prescriber, 2017
The clinical diagnosis of heart failure should be confirmed by echocardiogram to determine the underlying mechanism and to measure the left ventricular ejection fraction. Heart failure with reduced ejection fraction and heart failure with preserved ejection fraction have different treatments but are often indistinguishable clinically.
Ingrid Hopper, K. Easton
openaire +4 more sources
The clinical diagnosis of heart failure should be confirmed by echocardiogram to determine the underlying mechanism and to measure the left ventricular ejection fraction. Heart failure with reduced ejection fraction and heart failure with preserved ejection fraction have different treatments but are often indistinguishable clinically.
Ingrid Hopper, K. Easton
openaire +4 more sources